title: Treatment of HER2-positive breast cancer.
abstract: The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or amplified in ~15% of breast cancer patients and was identified a quarter century ago as a marker of poor prognosis. By 1998, antibody therapy targeting the HER2 pathway was shown to demonstrably improve progression-free and overall survival in metastatic disease, and in 2005 evidence of improvement in disease-free and overall survival from the first generation of trastuzumab adjuvant trials became available. However, not all patients with HER2 overexpression benefit from trastuzumab. Second-generation studies in metastatic disease led to the approval of several new HER2-targeted therapies using small molecule tyrosine kinase inhibitors such as lapatinib, new HER2/HER3 antibodies such as pertuzumab, and the new antibody chemotherapy conjugate ado-trastuzumab emtansine. These successes supported the launch of second-generation adjuvant trials testing single and dual HER2-targeted agents, administered concomitantly or sequentially with chemotherapy that will soon complete accrual. HER2-positive breast cancer in the setting of HER2-targeted therapy is no longer associated with poor prognosis, and recent guidance by the US Food and Drug Administration suggests that pathologic response to HER2-targeted therapy given preoperatively may allow an earlier assessment of their clinical benefit in the adjuvant setting. An adjuvant trial of trastuzumab in patient whose tumors express normal levels of HER2 and trials of single/dual HER2-targeting without chemotherapy are also ongoing. In this article, we review the current data on the therapeutic management of HER2-positive breast cancer.
authors.affiliation: Breast Cancer Program, The Johns Hopkins Kimmel Comprehensive Cancer Center Baltimore, MD, USA.
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: Figueroa-Magalhães
authors.affiliation: Breast Cancer Program, The Johns Hopkins Kimmel Comprehensive Cancer Center Baltimore, MD, USA.
authors.forename: Danijela
authors.initials: D
authors.lastname: Jelovac
authors.affiliation: Breast Cancer Program, The Johns Hopkins Kimmel Comprehensive Cancer Center Baltimore, MD, USA.
authors.forename: Roisin
authors.initials: R
authors.lastname: Connolly
authors.affiliation: Breast Cancer Program, The Johns Hopkins Kimmel Comprehensive Cancer Center Baltimore, MD, USA.
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Wolff
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: HER2-positive breast cancer; Lapatinib; Pertuzumab; Trastuzumab